Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA217676
Max Phase: Preclinical
Molecular Formula: C9H12O4
Molecular Weight: 184.19
Molecule Type: Small molecule
Associated Items:
ID: ALA217676
Max Phase: Preclinical
Molecular Formula: C9H12O4
Molecular Weight: 184.19
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C=C1C(=O)O[C@H](CCC)[C@H]1C(=O)O
Standard InChI: InChI=1S/C9H12O4/c1-3-4-6-7(8(10)11)5(2)9(12)13-6/h6-7H,2-4H2,1H3,(H,10,11)/t6-,7+/m1/s1
Standard InChI Key: SRQUTZJZABSZRQ-RQJHMYQMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: Yes | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 184.19 | Molecular Weight (Monoisotopic): 184.0736 | AlogP: 0.97 | #Rotatable Bonds: 3 |
Polar Surface Area: 63.60 | Molecular Species: ACID | HBA: 3 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 4.14 | CX Basic pKa: | CX LogP: 1.60 | CX LogD: -1.48 |
Aromatic Rings: 0 | Heavy Atoms: 13 | QED Weighted: 0.52 | Np Likeness Score: 1.76 |
1. Mai A, Rotili D, Tarantino D, Ornaghi P, Tosi F, Vicidomini C, Sbardella G, Nebbioso A, Miceli M, Altucci L, Filetici P.. (2006) Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties., 49 (23): [PMID:17154519] [10.1021/jm060601m] |
2. Sbardella G, Castellano S, Vicidomini C, Rotili D, Nebbioso A, Miceli M, Altucci L, Mai A.. (2008) Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases., 18 (9): [PMID:18434144] [10.1016/j.bmcl.2008.04.017] |
3. Mai A, Rotili D, Tarantino D, Nebbioso A, Castellano S, Sbardella G, Tini M, Altucci L.. (2009) Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases., 19 (4): [PMID:19144517] [10.1016/j.bmcl.2008.12.097] |
4. Lu W, Xiong H, Chen Y, Wang C, Zhang H, Xu P, Han J, Xiao S, Ding H, Chen Z, Lu T, Wang J, Zhang Y, Yue L, Liu YC, Zhang C, Yang Y, Jiang H, Chen K, Zhou B, Luo C.. (2018) Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors., 26 (20): [PMID:30297119] [10.1016/j.bmc.2018.07.048] |
5. Zhang R, Wang J, Zhao L, Liu S, Du D, Ding H, Chen S, Yue L, Liu YC, Zhang C, Liu H, Luo C.. (2018) Identification of novel inhibitors of histone acetyltransferase hMOF through high throughput screening., 157 [PMID:30145373] [10.1016/j.ejmech.2018.08.026] |
Source(1):